Adaptive Biotechnologies (ADPT) Invested Capital (2022 - 2026)

Adaptive Biotechnologies has disclosed Invested Capital across 5 years of filings, most recently posting $150.7 million for Q2 2026.

• In Q2 2026, Invested Capital fell 51.88% year-over-year to $150.7 million; the TTM figure through Jun 2026 stood at $150.7 million (down 51.88% YoY), while the FY2025 annual figure was $356.2 million, up 6.09% from the prior year.
• Invested Capital came in at $150.7 million for Q2 2026 at Adaptive Biotechnologies, down from $354.8 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $589.5 million in Q4 2022 to a low of $150.7 million in Q2 2026.
• Average Invested Capital over 5 years is $371.3 million, with a median of $356.2 million recorded in 2025.
• The largest YoY upside for Invested Capital was 9.58% in 2026 against a maximum downside of 51.88% in 2026.
• Over 5 years, Invested Capital stood at $589.5 million in 2022, then fell by 25.54% to $438.9 million in 2023, then declined by 23.51% to $335.8 million in 2024, then advanced by 6.09% to $356.2 million in 2025, then sank by 57.7% to $150.7 million in 2026.
• Per Business Quant data, the three most recent Invested Capital figures were $150.7 million in Q2 2026, $354.8 million in Q1 2026, and $356.2 million in Q4 2025.